Erchonia Pain-Treating Laser Device Gets FDA’s 510(k) Clearance

Melbourne, Fla.-based Erchonia has received 510(k) marketing clearance from the FDA for its laser treatment device for postoperative pain.

Participants in a clinical study who received the Erchonia low-energy laser treatments after surgery experienced approximately 50 percent less pain and consumed fewer narcotics than those in a placebo group.

The subjects experienced reduced pain levels immediately after surgery, and the relief continued at the one-week, two-week and one-month mark after their operations, the company said.